Emtricitabine/tenofovir disoproxil fumarate vs Tenofovir alafenamide/emtricitabine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Emtricitabine/tenofovir disoproxil fumarate · Truvada

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Partial signal

NCT00323544 · Phase 3 · completed

This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07584122 (registry estimate)

Reported efficacy

The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)

Result source: NCT00323544

Tenofovir alafenamide/emtricitabine · Descovy

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Reliable signal

NCT02121795 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin.

Next expected readout: January 2027 · NCT07349758 (registry estimate)

Reported efficacy

Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) (met)

Result source: NCT02842086

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmtricitabine/​tenofovir disoproxil fumarateTenofovir alafenamide/​emtricitabine
HIV-1 RNA below 50 copies/mL (week 48)83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
94.3% vs 93%vs FTC/TDFwk 48 · n 333NCT02121795
31 other results
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.4% vs 97.8% wk 24 · n 183 · Phase 3 · primary NCT02605954
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT003235440.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246
CD4 count, change (week 48)224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
60 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850

HIV-1 RNA below 50 copies/mL (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
Tenofovir alafenamide/​emtricitabine
94.3% vs 93%vs FTC/TDFwk 48 · n 333NCT02121795
31 other results
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.4% vs 97.8% wk 24 · n 183 · Phase 3 · primary NCT02605954
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594

HIV-1 RNA 50 copies/mL or more (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
—Not posted · NCT00323544
Tenofovir alafenamide/​emtricitabine
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246

CD4 count, change (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
Tenofovir alafenamide/​emtricitabine
60 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Emtricitabine/tenofovir disoproxil fumarate: 6 of 6 rows · Tenofovir alafenamide/emtricitabine: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmtricitabine/​tenofovir disoproxil fumarate
Rows use multiple source trials
Tenofovir alafenamide/​emtricitabine
Rows use multiple source trials
CD4
absolute change · count
Maintenance
189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.a,b,c
NCT00369941 · Phase 3 · registry result, not featured evidence
258 vs 188 DTG + F/TAF count @ 48wka,b,c
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA LT 50 Copies
responder rate · % of participants
Maintenance
93% (n=154) vs 91.1% (n=156) ABC/3TC @ 48wkd,b
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
94.4% (n=89) vs 76.1% (n=46) SBR @ 48wkd,b
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
24.7%e
NCT00458393 · Phase 3
show 15 more results
16%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
24%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
0%200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
24.2%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
79.9%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01195467 · Phase 3 · registry result, not featured evidence
19.5%
NCT00625404 · Phase 3 · registry result, not featured evidence
25.5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
8.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
11.4%F/TAF + 3rd Agentf
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
23.5%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
20%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
5.1%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
12.6%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
4%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
1.9%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
4.4%
NCT04782180 · Phase 4 · registry result, not featured evidence
18.7%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
17.1%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
5.3%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
5.4%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
0%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
9.1%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
3.3%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
8%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
21.2%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
34%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
30.8%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
19.4%
NCT01565850 · Phase 2 · registry result, not featured evidence
3%
NCT03960645 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—e
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
8%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
—
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
1.6%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
7.4%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
—
NCT01195467 · Phase 3 · registry result, not featured evidence
—
NCT00625404 · Phase 3 · registry result, not featured evidence
5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
—NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
—NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
1.5%F/TAF + 3rd Agentf
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
4.2%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
0.7%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
0.7%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
2.8%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
—Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—
NCT04782180 · Phase 4 · registry result, not featured evidence
1.2%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
2.7%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
—Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
—E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
1.9%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
0%
NCT01565850 · Phase 2 · registry result, not featured evidence
—
NCT03960645 · Phase 1 · registry result, not featured evidence
Serious AEs
7.5%e
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
0%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
7.7%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
0%Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
9.7%
NCT00323492 · Phase 4 · registry result, not featured evidence
11.7%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
18.6%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
10%
NCT01195467 · Phase 3 · registry result, not featured evidence
3.2%
NCT00625404 · Phase 3 · registry result, not featured evidence
20.3%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
10.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
—F/TAF + 3rd Agentf
NCT02121795 · Phase 3 · combination
show 52 more results
8.7%F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
6.1%Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
9.7%Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
—F/TAF
NCT02469246 · Phase 3
19.6%F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
0%Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
0%Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
—E/C/F/TAF
NCT01797445 · Phase 3
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
—E/C/F/TAF
NCT01815736 · Phase 3
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
22.7%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
16.7%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
20%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
13.5%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
3.7%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%
NCT04782180 · Phase 4 · registry result, not featured evidence
20%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
14%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
4.5%Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
9.5%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
16.2%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
10.7%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
10.8%Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
16.2%HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
0%HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
4.8%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
10.1%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
6%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
7.7%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
7.5%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
13.5%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.9%
NCT01565850 · Phase 2 · registry result, not featured evidence
18.2%
NCT03960645 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
e
pharyngitis 20.2% (placebo 22.9%)
parasitic infection intestinal 18.8% (placebo 17.6%)
alanine aminotransferase increased 12.3% (placebo 12.6%)
NCT00458393 · Phase 3
show 13 more results
erectile dysfunction 4.8%
gastroenteritis 4.8%
headache 4.8%
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
gastroenteritis 5.3%
pulmonary embolism 5.3%
anxiety 0%
NCT02401230 · Phase 4 · registry result, not featured evidence
neutrophil count decreased 38%
blood albumin decreased 35.6%
blood sodium decreased 34%
NCT01380080 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 9%
diarrhea 8.4%
cough 5.2%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 9.7%
abdominal pain 4.2%
bronchitis 4.2%
NCT00323492 · Phase 4 · registry result, not featured evidence
100 mg
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · registry result, not featured evidence
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 22.1%
jaundice 22.1%
ocular icterus 20.1%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
bilateral arm pain 2.5%
cellulitis 2.5%
diarrhoea 2.5%
NCT01195467 · Phase 3 · registry result, not featured evidence
blood phosphorus decreased 19.4% (placebo 18.3%)
aspartate aminotransferase increased 13.1% (placebo 11.5%)
headache 13.1% (placebo 14.3%)
NCT00625404 · Phase 3 · registry result, not featured evidence
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3 · registry result, not featured evidence
cough 23.1%
neutrophil count decreased 23.1%
rash 23.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 27.3%
rash 26.5%
cough 24.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
f
upper respiratory tract infection 16.2%
diarrhoea 13.2%
nasopharyngitis 12.9%
NCT02121795 · Phase 3 · combination
show 45 more results
nasopharyngitis 12.1%
back pain 9.1%
syphilis 9.1%
NCT02121795 · Phase 3
onychomycosis 9.7%
sinusitis 9.7%
arthralgia 6.5%
NCT02121795 · Phase 3
nasopharyngitis 20.4%
upper respiratory tract infection 12.9%
cough 12.1%
NCT02469246 · Phase 3
nasopharyngitis 20%
renal colic 20%
rhinitis 20%
NCT02469246 · Phase 3
spinal pain 16.7%
arthralgia 0%
back pain 0%
NCT02469246 · Phase 3
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3
upper respiratory tract infection 16.1%
bronchitis 15.3%
arthralgia 14%
NCT01818596 · Phase 3
hyperlipidaemia 33.3%
pain in extremity 33.3%
anogenital warts 16.7%
NCT01818596 · Phase 3
upper respiratory tract infection 40%
respiratory tract infection 38%
nausea 30%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 26.9%
vomiting 25%
respiratory tract infection 21.2%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 51.9%
cough 33.3%
nasopharyngitis 18.5%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
arthralgia 9%
diarrhoea 4.5%
headache 4.5%
NCT02605954 · Phase 3 · registry result, not featured evidence
diarrhoea 10.4%
headache 8.2%
vitamin d deficiency 7.1%
NCT02605954 · Phase 3 · registry result, not featured evidence
urinary tract infection 13.5%
upper respiratory tract infection 12.2%
arthralgia 9.5%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
cough 13.5%
headache 10.8%
nausea 8.1%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
hyperbilirubinaemia 3.6% (placebo 0%)
influenza 3.6% (placebo 0%)
jaundice 3.6% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
nausea 16.7% (placebo 0%)
arthralgia 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 29.7% (placebo 0%)
malaria 13.5% (placebo 0%)
headache 10.8% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 23%
nasopharyngitis 12.2%
diarrhoea 10.8%
NCT02071082 · Phase 3 · registry result, not featured evidence
dental caries 33.3%
diarrhoea 33.3%
herpes zoster 33.3%
NCT02071082 · Phase 3 · registry result, not featured evidence
acute sinusitis 19%
bronchitis 14.3%
sinusitis 14.3%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
back pain 12.4%
upper respiratory tract infection 11.2%
bronchitis 6.7%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
cough 24%
upper respiratory tract infection 22%
vomiting 16%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 60%
cough 50%
nasal obstruction 30%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
injection site erythema 48.1%
injection site swelling 32.7%
injection site pain 28.8%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
injection site erythema 34%
injection site swelling 34%
injection site pain 26.4%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
covid-19 21.2%
influenza 21.2%
headache 17.3%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 21.4%
upper respiratory tract infection 15.5%
fatigue 13.6%
NCT01565850 · Phase 2 · registry result, not featured evidence
back pain 12.1%
gestational diabetes 12.1%
anaemia 9.1%
NCT03960645 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 3 versus Phase 4.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 47 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Emtricitabine/tenofovir disoproxil fumarate

Cumulative Incidence of Death 4.8 vs 5.2 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
Cumulative Incidence of Disease Progression 16.6 vs 11.3 IPT Cumulative probability per 100 persons @ 96wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV Disease Progression 17.1 vs 12.5 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
show 1 more result
19.3 vs 15.3 IPT Cumulative probability per 100 persons @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies 0% (n=424) vs 0.01% (n=426) IPT @ 0wk
event count · % of participants
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
0.46% (n=424) vs 0.49% (n=426) IPT @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.84% (n=424) vs 0.85% (n=426) IPT @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.87% (n=424) vs 0.89% (n=426) IPT @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
CD4+ Cell 18 vs 19 IPT cells/uL @ 0wk
event count · cells/uL
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
74 vs 76 IPT cells/uL @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
121 vs 121 IPT cells/uL @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
176 vs 172 IPT cells/uL @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 86.4% (n=154) vs 83.3% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
99.2% (n=154) vs 97.2% (n=156) ABC/3TC @ 48wk
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA LT 200 Copies 84.4% (n=154) vs 82.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 79.9% (n=154) vs 77.6% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
Peak VO2 Change mL/Min 2.2 vs 2.8 Combivir or Trizivir kg @ 24wk200/300 mg, Daily, by Mouth
absolute change · kg
NCT00960622 · Phase 4 · registry result, not featured evidence
LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence
HDL-C Change mg/dL 3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

Tenofovir alafenamide/emtricitabine

HIV-1 RNA Less Than 20 Copies 91.6% (n=333) vs 90.9% (n=330) FTC/TDF @ 48wk
responder rate · % of participants
NCT02121795 · Phase 3 · combination
show 6 more results
83.5% (n=333) vs 86.1% (n=330) FTC/TDF @ 96wk
NCT02121795 · Phase 3 · combination
85.7% (n=280) vs 87.3% (n=276) ABC/3TC @ 48wk
NCT02469246 · Phase 3
80.4% (n=280) vs 86.2% (n=276) ABC/3TC @ 96wk
NCT02469246 · Phase 3
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3
90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
NCT01815736 · Phase 3
HIV-1 RNA Ge50 Copies 1.8% (n=280) vs 0.7% (n=276) ABC/3TC @ 48wk
responder rate · % of participants
NCT02469246 · Phase 3
show 2 more results
2.5% (n=280) vs 1.1% (n=276) ABC/3TC @ 96wk
NCT02469246 · Phase 3
0.4% (n=284) vs 1.1% (n=281) DTG + F/TAF @ 48wk
NCT03110380 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less Than 50 Copies 95% (n=242) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01818596 · Phase 3
show 34 more results
83.3% (n=6) @ 24wk
NCT01818596 · Phase 3
93% (n=242) @ 48wk
NCT01818596 · Phase 3
100% (n=6) @ 48wk
NCT01818596 · Phase 3
88.4% (n=242) @ 96wk
NCT01818596 · Phase 3
100% (n=6) @ 96wk
NCT01818596 · Phase 3
81.4% (n=242) @ 144wk
NCT01818596 · Phase 3
100% (n=6) @ 144wk
NCT01818596 · Phase 3
90% (n=50) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
92% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
98.1% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
96.3% (n=27) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
96.3% (n=27) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
90% (n=50) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
92% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
96.3% (n=27) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
96.3% (n=27) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
93.8% (n=48) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
95.8% (n=48) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
96.3% (n=27) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
96.3% (n=27) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
84.5% (n=278) @ 96wk
NCT01705574 · Phase 3 · registry result, not featured evidence
86.9% (n=183) @ 48wk
NCT02605954 · Phase 3 · registry result, not featured evidence
86.5% (n=37) @ 24wk
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
97.3% (n=37) @ 48wk
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
96% (n=50) @ 24wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
100% (n=10) @ 24wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
90% (n=50) @ 48wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
100% (n=10) @ 48wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
100% (n=32)
NCT03960645 · Phase 1 · registry result, not featured evidence
HIV-1 RNA Less 400 94% (n=50) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 9 more results
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV-1 RNA -3.25 copies/mL @ 24wk
absolute change · copies/mL
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 1 more result
-3.26 copies/mL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
CD4+ 191 cells/uL @ 24wk
absolute change · cells/uL
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 12 more results
224 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-118 cells/uL @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-66 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-137 cells/uL @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-179 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-32 cells/uL @ 48wk
NCT02605954 · Phase 3 · registry result, not featured evidence
76 cells/uL @ 24wk
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
125 cells/uL @ 48wk
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
-72 cells/uL @ 24wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
-85 cells/uL @ 24wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
-43 cells/uL @ 48wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
-41 cells/uL @ 48wk
NCT02276612 · Phase 2/3 · registry result, not featured evidence
CD4+ 7.7% (n=50) @ 24wk
absolute change · percentage points
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 5 more results
9.3% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-0.8% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-0.6% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0% (n=27) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0.2% (n=27) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV RNA Less Than 50 Copies 89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 2 more results
84.1% (n=320) vs 86.5% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
81.9% (n=320) vs 84% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA -3.07 vs -3.12 DTG + F/TAF log @ 48wk
absolute change · log
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 26 more results
-3.08 vs -3.1 DTG + F/TAF log @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.06 vs -3.11 DTG + F/TAF log @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.11 vs -3.07 ABC/DTG/3TC log @ 48wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-3.11 vs -3.1 ABC/DTG/3TC log @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-0.72 vs -0.04 placebo log @ 1.428571wk
NCT01967940 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.04 placebo log @ 1.428571wk
NCT01967940 · Phase 3 · registry result, not featured evidence
-2.92 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.04 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.01 vs -3.07 B/F/TAF log @ 28wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.96 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.06 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.02 vs -3.04 B/F/TAF log @ 38wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.95 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.12 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.85 vs -3.08 B/F/TAF log @ 54wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.08 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-2.96 vs -3.09 B/F/TAF log @ 80wk
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
-3.03 vs -3.15 DTG + F/TAF log @ 12wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.12 DTG + F/TAF log @ 24wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.09 vs -3.11 DTG + F/TAF log @ 48wk
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
-3.2 vs -3.26 E/C/F/TDF log @ 24wk
NCT01497899 · Phase 2 · registry result, not featured evidence
-3.22 vs -3.33 E/C/F/TDF log @ 48wk
NCT01497899 · Phase 2 · registry result, not featured evidence
-3.2 vs -3.18 DRV+COBI+FTC/TDF log @ 24wk
NCT01565850 · Phase 2 · registry result, not featured evidence
-3.27 vs -3.26 DRV+COBI+FTC/TDF log @ 48wk
NCT01565850 · Phase 2 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine/tenofovir disoproxil fumarate's landscape · Tenofovir alafenamide/emtricitabine's landscape